SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors are effective antidiabetic
therapies in patients with type 2 diabetes mellitus and are associated with improved …
therapies in patients with type 2 diabetes mellitus and are associated with improved …
Genetics of diabetes mellitus and diabetes complications
Diabetes is one of the fastest growing diseases worldwide, projected to affect 693 million
adults by 2045. Devastating macrovascular complications (cardiovascular disease) and …
adults by 2045. Devastating macrovascular complications (cardiovascular disease) and …
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
Summary Background Both DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced
(assessing empagliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) …
(assessing empagliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) …
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver
disease and affects nearly a quarter of the global population. The objective of this work was …
disease and affects nearly a quarter of the global population. The objective of this work was …
Japanese clinical practice guideline for diabetes 2019
E Araki, A Goto, T Kondo, M Noda, H Noto… - Diabetology …, 2020 - Springer
The current guideline represents the 6th edition of the “Japanese Clinical Practice Guideline
for Diabetes” which has been revised every three years since its first appearance in 2004 to …
for Diabetes” which has been revised every three years since its first appearance in 2004 to …
[HTML][HTML] Dapagliflozin in patients with chronic kidney disease
HJL Heerspink, BV Stefánsson… - … England Journal of …, 2020 - Mass Medical Soc
Background Patients with chronic kidney disease have a high risk of adverse kidney and
cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease …
cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease …
Cardiovascular outcomes with ertugliflozin in type 2 diabetes
Background The cardiovascular effects of ertugliflozin, an inhibitor of sodium–glucose
cotransporter 2, have not been established. Methods In a multicenter, double-blind trial, we …
cotransporter 2, have not been established. Methods In a multicenter, double-blind trial, we …
High blood pressure and cardiovascular disease
FD Fuchs, PK Whelton - Hypertension, 2020 - Am Heart Assoc
Fragmented investigation has masked the overall picture for causes of cardiovascular
disease (CVD). Among the risk factors for CVD, high blood pressure (BP) is associated with …
disease (CVD). Among the risk factors for CVD, high blood pressure (BP) is associated with …
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes …
F Cosentino, PJ Grant, V Aboyans… - European heart …, 2020 - academic.oup.com
Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …
exercising their clinical judgment, as well as in the determination and the implementation of …
2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of …
SR Das, BM Everett, KK Birtcher, JM Brown… - Journal of the American …, 2020 - jacc.org
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk
Reduction in Patients With Type 2 Diabetes: A Report of the American College of …
Reduction in Patients With Type 2 Diabetes: A Report of the American College of …